SCHEMBL18174564

SCHEMBL18174564

Cc1cnccc1-c1ccc(-c2c3ccccc3c(-c3ccc(-c4ccncc4C)cc3)c3ccccc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.49
CYP17A1 P05093 4/20 0.41
CYP1A2 P05177 3/20 0.41
CYP19A1 P11511 1/20 0.41
DHODH Q02127 1/20 0.40
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
IMPDH2 P12268 1/20 0.40
S1PR1 P21453 1/20 0.40
S1PR3 Q99500 1/20 0.40
RPS6KA3 P51812 2/20 0.39
TNF P01375 1/20 0.39
MAPK14 Q16539 1/20 0.38
HAVCR2 Q8TDQ0 1/20 0.38
MAPK1 P28482 2/20 0.38
PDE2A O00408 1/20 0.38
PDE10A Q9Y233 1/20 0.38
CHEK1 O14757 1/20 0.38
RPS6KA5 O75582 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15161039 0.95 GRM4 (0.46) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL18174625 0.94 DHODH (0.48) GRM4CYP17A1CYP1A2DHODHRPS6KA3
SCHEMBL18174776 0.92 GRM4 (0.43) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL18174758 0.91 GRM4 (0.43) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL18174750 0.91 GRM4 (0.43) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL9612937 0.89 TNF (0.49) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL18174626 0.89 GRM4 (0.42) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL18174759 0.88 CYP17A1 (0.46) GRM4CYP17A1CYP1A2DHODHS1PR1
SCHEMBL9612933 0.88 TNF (0.48) GRM4CYP17A1CYP1A2CYP19A1DHODH
SCHEMBL18174551 0.88 PIK3CA (0.46) GRM4CYP17A1CYP1A2CYP19A1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9478750-B2 Anthracene derivative and organic electroluminescent element using the same JNC CORPORATION (JP) 2016-10-25 US disclosed
US-9478750-B2 Anthracene derivative and organic electroluminescent element using the same JNC CORPORATION (JP) 2016-10-25 US disclosed
US-20150203469-A1 ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF CELGENE CORPORATION 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203469-A1 ISOTOPOLOGUES OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2-6-DIONE AND METHODS OF PREPARATION THEREOF AQP3, CYP2D6, CYP3A5 GRM4 3178/4885CYP17A1 1790/4885CYP1A2 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.